An Clinicopathological and Survival Analysis of Non-Squamous Cervical Cancers at Ahpgic

B L Nayak1, A K Padhy1, J J Mohapatra1, M R Mohapatra1, J Parija1, R Das1, S Mohanty1, S S Pattnaik1*, S K Giri1, N Panda1, S.N Senapathi1, L Pattnaik1, L Sarangi1, S Padhi1, S Samantray1, S Panda1, N Rout1, T Kar1, L Das1, Duttaswar Hota1, P C Mohapatra1, P Devi1

1Department of gynae oncology ahpgic Cuttack, India

*Corresponding author
S.S Pattnaik, M.B.B.S, (SCBMCH), Dept. of Gynaecology, India.

Submitted: 27 Apr 2022; Accepted: 23 May 2022; Published: 30 May 2022

Citation: S S Pattnaik, B L Nayak, A K Padhy, J J Mohapatra, M R Mohapatra, et al, (2022). An Clinicopathological and Survival Analysis of Non-Squamous Cervical Cancers at Ahpgic. Int J Cancer Res Ther, 7(2), 92-101.

Abstract

Aim and Objective: An clinicopathological and survival analysis 22 cases cases of no squamous carcinomas of cervix from 2010-2020

Primary objective: is to analyse the extent of microscopic parametrial involvement in early invasive non squamous carcinoma with respect to age, size of lesion, depth of invasion.

To analyse the nodal status in clinically early invasive nonsquamous carcinoma with respect to other variable i.e age, tumor size, depth of invasion, parametrial involvement.

Secondary Objective: was to analyse the survival status, of after radical hysterectomy and adjuvant therapy.

Material and Methods: The hps confirmed cases of no squamous carcinoma of cervix were included in the study and few cases were ihc confirmed.

Inclusion Criteria: Primary non-squamous carcinoma of cervix hps confirmed.

Exclusion Criteria: Squamous carcinoma and metastatic carcinoma of cervix

Methods: Regression analysis chi square, log rank test. Kaplan Meyers curve was used for survival analysis.

Results: On regression analysis with dependent variable as the pelvic node was analysed with age, depth of invasion and size of lesion and parametrium, none of factors were significantly influencing the nodal status. Similarly, the parametrium positivity taken as the dependent variable was analysed with age, size of lesion, depth of invasion. None of the factors could predict the parametrial involvement. Overall 5-year survival probability for the patients is 0.770 i.e 55 months with 95% CI (0.570, 1.000). Here, the 5-year survival probability for the patients with parametrium positive status is 0.917 i.e 48 months 95% CI (0.773, 1.000). The log rank test for change in survival between two parametrium groups i.e., negative and positive patients gives chi-square value 3.59 (d.f =1, p-value = 0.06), which indicates two groups do not differ in their survival.

Disease free survival of the parametrium –ve/ parametrium+ve(60/24 mths). The log rank test for change in survival between two parametrium groups i.e., negative and positive patients gives chi-square value 2.8 (d.f.=1, p-value = 0.1), which indicates two groups do not differ in their disease free survival.

Keywords: Capecitabine, Xeloda, Hypertriglyceridemia, Serum Triglyceride Levels, Drug Adverse Effect
**Introduction**

The global incidence of cervical cancer burden is disproportionately high in low and middle income countries, where 83% of all new cases and 85% of cervical cancer death occur [1]. India accounts for nearly one fourth of the world’s cervical cancer deaths, with 60,078 death and 96,922 new cases in 2018 [2, 3]. Cancer cervix is the most probable cause of maternal mortality in Indian women [4].

Adenocarcinoma represent 20-25% of cervical cancers in the industrialized countries. Most of this is due to relative decrease in incidence of squamous cell carcinoma. In contrast to squamous carcinoma, smoking does not increase the risk adenocarcinoma. Squamous and non-squamous differ in HPV status [5]. HPV 18 accounts for 50% of non-squamous cell cancer (adenocarcinoma) of 15% of squamous cell carcinomas.

Management of adenocarcinoma is same as squamous. Whereas squamous disseminate via lymphatics and adenocarcinoma haematogenous route [6]. This is evident as after lymphatic dissemination adenocarcinoma has poor prognosis compared to squamous cell carcinoma [7].

Other evidence in support of haematogenous spread is the largest series of surgically treated cervical cancers demonstrated a significantly higher rate of ovarian metastasis with adenocarcinoma (5% vs 0.8%, p<0.01).

A study of 367 pts of adenocarcinoma from M.D ANDERSON hospital reported a higher rate of distant metastasis for stage II (46% vs 13%) and stage III disease (38% vs 21%) when compared squamous carcinoma.

There are very few studies regarding the prognostic factors i.e. clinical and pathological factors influencing the parametrium positivity and nodal status of non-squamous carcinoma. That is the reason they are overtreated by multimodality i.e. (radical surgery with adjuvant) treatment.

Studies done by M.D Anderson on 29 patients of adenosquamous and 97 pts of adenocarcinoma in stage 1b1., with radical hysterectomy. On follow up time to recurrence (7.9 months vs 19 months p<0.01)

A STUDY OF 163 adenocarcinoma and adenosquamous carcinoma with stage 1A2 to IIIB disease treated by radical hysterectomy with or without adjuvant radiation found no difference in recurrence rate or patterns of recurrences between the two groups, in both low risk, intermediate risk high-risk group [8].

One hundred patients met the inclusion criteria. The median age was 35 years (range 22–65), and 51% (51/100) had pure high-grade neuroendocrine carcinoma. No patient had a tumor >4 cm or suspected parametrial or nodal disease before surgery. Ten patients (10%) had microscopic parametrial compromise in the final surgical specimens. Ninety-four (94%) patients underwent nodal assessment, and 19 (19%) had positive nodes. Ten patients underwent both sentinel lymph node biopsy and pelvic lymphadenectomy, and none had false-negative findings. Patients with parametral compromise were more likely to have positive pelvic nodes (80% vs 12%, p<0.0001), and a positive vaginal margin (20% vs 1%, p=0.03). All patients with parametral compromise had lymphovascular space invasion (100% vs 73%, p=0.10). Of the 100 patients, 95 (95%) were recommended adjuvant therapy and 89 (89%) were known to have received it. Adjuvant pelvic radiotherapy reduced the likelihood of local recurrence by 62%.

**Descriptive Statistics**

A total 22 cases of non-squamous carcinoma were taken for statistical evaluation. The median age incidence was 46 yrs. The youngest age was 28 yrs and maximum age 62 yrs. 9 (40.9) were <46 yrs and no’s cases more than 46 yrs was 13 (59.1). Of the 100 cases, 4 (18.2%) cases were multiparous and 4 (18.2%) cases were nulliparous. The spectrum of presentation varied from pmb 9 (40.9) cases, watery discharge 9 (22) no cases, aub were 4 (18.2) and pcb 4 (18.2) TABLE 1

**Table 1: Clinical Statistics**

| Variables   | Values |
|-------------|--------|
| Age (in years) | Mean ± SD 46.04 ± 9.20 |
| Median       | 46     |
| Range (Max, Min) | 34 (62, 28) |
| < 46, n (%)  | 09 (40.9) |
| ≥ 46, n (%)  | 13 (59.1) |
| Parity, n (%)| Null parity 04 (18.2) |
|             | Multi parity 18 (81.8) |
| Symptoms, n (%)| PMB 09 (40.9) |
|              | WD 05 (22.7) |
|              | AUB 04 (18.2) |
|              | PCB 04 (18.2) |
Of the total 22 cases all 22 (100) (%)) underwent; laparotomy 20 (90.9) cases underwent type 2 radical hysterectomy, and 2 cases underwent type 3 radical hysterectomy. There were intraoperative surgical complications and 22(100) post-operative complications. There were 4 (18.2) cases with a high residual urine and rest had minor blade dysfunction18 (81.8) table -2. The high residual urine post op for the four cases wee200 ml, 90ml, 150ml, 150ml. After adjuvant treatment all four case required recatherisation.

Table 2: Surgical Statistics

| Variables                          | Values            |
|-----------------------------------|-------------------|
| Surgical Procedure, n (%)         |                   |
| Laparotomy                        | 22 (100)          |
| Radical Hysterectomy (type-2)     | 20 (90.9)         |
| Radical Hysterectomy (type-3)     | 02 (09.1)         |
| Laparoscopy                       | NIL               |
| Surgical Complications, n (%)     |                   |
| Intra op                          | NIL               |
| Post op                           | 22 (100)          |
| Bowel                             | NIL               |
| Bladder                           | 22 (100)          |
| Bladder Complications (HIGH RESIDUAL URINE) | 04 (18.2) |
| Bladder Complications (MINOR BLADDER DYSFUNCTIONS) | 18 (81.8) |

Table 3: Histopathological Statistics

| Variables                          | Values            |
|-----------------------------------|-------------------|
| Size of lesion (in cm)            |                   |
| Mean ± SD                         | 3.46 ± 1.5        |
| Median                            | 3                 |
| Range (Max, Min)                  | 5.5 (7, 1.5)      |
| < 3, n (%)                        | 07 (33.3)         |
| ≥ 3, n (%)                        | 15 (66.7)         |
| Margins, n (%)                    |                   |
| Positive                          | 10 (45.4)         |
| Negative                          | 12 (54.6)         |
| LVSI, n (%)                       |                   |
| Positive                          | 07 (33.3)         |
| Negative                          | 15 (66.7)         |
| Grade, n (%)                      |                   |
| Grade-1                           | 10 (45.4)         |
| Grade-2                           | 06 (27.3)         |
| Grade-3                           | 06 (27.3)         |
| Nodal Status, n (%)               |                   |
| Pelvic                            |                   |
| Negative                          | 14 (63.6)         |
| Positive                          | 08 (36.4)         |
| Internal iliac                    | 04                |
| Obturator                         | 01                |
| Upper External iliac              | 02                |
| Low External iliac                | 01                |
|                                | Common iliac | NIL |
|--------------------------------|--------------|-----|
| **Para aortic**                |              |     |
| Negative                       | 20 (90.9)    |     |
| Positive                       | 02 (09.1)    |     |
| **Depth of stomal invasion, n (%)** |            |     |
| < 5 mm                         | 07 (31.8)    |     |
| ≥5 mm                          | 15 (68.2)    |     |
| **Parametrium, n (%)**         |              |     |
| Positive                       | 05 (22.7)    |     |
| Negative                       | 17 (77.3)    |     |
| **Adnexa, n (%)**              |              |     |
| Positive                       | NIL          |     |
| Negative                       | 22 (100)     |     |
| **Stage, n (%)**               |              |     |
| Stage-1                        | 17 (77.3)    |     |
| A                              | NIL          |     |
| B1                             | 06           |     |
| B2                             | 09           |     |
| B3                             | 02           |     |
| Stage-2                        | NIL          |     |
| Stage-3                        | 05 (22.7)    |     |
| C1                             | 04           |     |
| C2                             | 01           |     |
| Stage-4                        | NIL          |     |

There were 2 (9.09%) were adenosquamous, 1 (4.55%) case was basaloid carcinoma and rest 20 (91%) cases were adenocarcinoma.

The median size of the lesion is 3 cm. 7 (33.3%) cases we less than 3 and 15 (66.7%) cases ae more than 3cm mains positive in 10 (45.4%) cases and negative in 12 (54.6%) lvis positive in 7 (31.8%) and 15 cases (66.7%) negative. No. of grade 1 10 (45.4%) and grade 2 6 (27.3%) and grade 3 6 (27.3%). Nodal status shows the pelvic node 8 (36.4%). Paaaortic 2 (9.1%). The depth of invasion >5 mm 25 (31.8%) and <5 mm 7 (68.2%).

The parametrium was positive in 5 cases (22.7%) cases was negative in 17 (77.3%) cases adnexa was not positive in any of cases 17 were in stage 1. With no case in 1a, 6 cases in 1b1, 9 cases in 1b2 and 2 cases in 1b3. There were 5 cases in stage 3. None of the cases presented in stage 2 and stage 4.

**Figure: 1** Adenocarcinoma of Cervix
Table 4: Regression Analysis

| Coefficients: | Estimate (β) | Std. Error | z-value | OR   | Pr(>|z|) |
|---------------|--------------|------------|---------|------|---------|
| (Intercept)   | -16.807      | 8.412      | -1.998  | .000 | 0.0457  |
| Age           | 0.228        | 0.142      | 1.612   | 1.257| 0.107   |
| Pelvic node   | 3.407        | 2.210      | 1.541   | 30.163| 0.123   |
| Sizeoflesion  | 0.778        | 0.512      | 1.519   | 2.177| 0.129   |

Variable(s):
Dependent Variable: Parametrium
Predictor Variable: Age, Pelvic node, Sizeoflesion.

Not a single predictor variable is significant in predicting Parametrium Status.

Table 5: Regression Analysis

| Coefficients: | Estimate (β) | Std. Error | z-value | OR   | Pr(>|z|) |
|---------------|--------------|------------|---------|------|---------|
| (Intercept)   | 3.427        | 3.824      | 0.896   | 30.784| 0.370   |
| Age           | -0.118       | 0.073      | -1.607  | 0.889| 0.108   |
| Parametrium   | 2.637        | 1.775      | 1.486   | 13.97 | 0.137   |
| Sizeoflesion  | 0.173        | 0.380      | 0.454   | 1.189 | 0.650   |
| Depthofinvasion| -0.227      | 1.306      | -0.174  | 0.797| 0.862   |

Variable(s):
Dependent Variable: Pelvic node
Predictor Variable: Age, Parametrium, Sizeoflesion, Depthofinvasion

Not a single predictor variable is significant in predicting Pelvic nodal status.
Table 6: Survival Statistics

| Variables          | Values     |
|--------------------|------------|
| Lost To Follow-up, n (%) | 03 (13.6) |
| NAD, n (%)          | 16 (72.8)  |
| Death, n (%)        | 03 (13.6)  |

The no. of cases lost to follow up 3(13.6%). 16 cases were normal on follow up and 3 cases succumbed (13.6%)

Survival Analysis

Table: 7 Overall Survival

| Time | No of Patients at risk | No of event(s) | Survival Probability | St. Error | Lower 95% CI | Upper 95% CI |
|------|------------------------|----------------|----------------------|-----------|-------------|-------------|
| 48   | 15                     | 1              | 0.933                | 0.064     | 0.815       | 1.000       |
| 50   | 12                     | 1              | 0.856                | 0.095     | 0.688       | 1.000       |
| 55   | 10                     | 1              | 0.770                | 0.118     | 0.570       | 1.000       |

Here, overall 5-year survival probability for the patients is 0.770 i.e 55 months with 95% CI (0.570, 1.000).

Table 8: Survival Status of the Patients with Parametrium Negative

| Time | No of Patients at risk | No of event(s) | Survival Probability | St. Error | Lower 95% CI | Upper 95% CI |
|------|------------------------|----------------|----------------------|-----------|-------------|-------------|
| 48   | 12                     | 1              | 0.917                | 0.079     | 0.773       | 1.000       |

Here, the 5-year survival probability for the patients with parametrium positive status is 0.917 i.e 48 months 95% CI (0.773, 1.000).

Table 9: Survival Status of the Patients with Parametrium Negative

| Time | No of Patients at risk | No of event(s) | Survival Probability | St. Error | Lower 95% CI | Upper 95% CI |
|------|------------------------|----------------|----------------------|-----------|-------------|-------------|
| 50   | 3                      | 1              | 0.667                | 0.272     | 0.299       | 1.000       |
| 55   | 2                      | 1              | 0.333                | 0.272     | 0.067       | 1.000       |

Here, the 5-year survival probability for the patients with parametrium negative status is 0.333 i.e 55 months with 95% CI (0.067, 1.000).

Table 10: Log-Rank Test Outcomes for Survival Differences

| Covariates | Category | Num. of Patient | Observed Event | Expected Event | (O-E)^2 / E | Chisq. Value | d.f. | p-value |
|------------|----------|-----------------|----------------|----------------|-------------|--------------|------|---------|
| parametrium| Negative | 18              | 1              | 2.35           | 0.776       | 3.59         | 1    | 0.06    |
|            | Positive | 4               | 2              | 0.65           | 2.804       |              |      |         |

The log rank test for change in survival between two parametrium groups i.e., negative and positive of cervical cancer patients gives chi-square value 3.59 (d.f.=1, p-value = 0.06), which indicates two groups do not differ in their survival.
Figure 1: Kaplan-Meier Plot for Overall Survival of Cervical Cancer Patients

Figure 1 Shows the proportion of individuals who have survived up to the specified time in the solid black line and their 95% confidence interval in black dashed lines.

Figure 1: Kaplan-Meier Plot of the Patients with (i) Parametrium Positive (Left) and (ii) Parametrium Negative (Right) of the Cervical Cancer Patients.

Figure 2 Shows the proportion of individuals who have survived up to the specified time in the solid black line and their 95% confidence interval in black dashed lines.
Overall, 5-year disease-free survival

| time | No of Patients at risk | No of event(s) | Survival Probability | St. Error | lower 95% CI | upper 95% CI |
|------|------------------------|----------------|----------------------|-----------|--------------|--------------|
| 24   | 21                     | 1              | 0.952                | 0.046     | 0.866        | 1.000        |
| 60   | 10                     | 2              | 0.762                | 0.126     | 0.551        | 1.000        |

KM plot for overall 5-year disease-free survival with & without recurrence lines

5-year disease-free survival of parametrium-ve patients

| time | No of Patients at risk | No of event(s) | Survival Probability | St. Error | lower 95% CI | upper 95% CI |
|------|------------------------|----------------|----------------------|-----------|--------------|--------------|
| 24   | 17                     | 1              | 0.941                | 0.057     | 0.836        | 1.000        |

KM plot for 5-year disease-free survival of parametrium-ve patients with & without recurrence lines
**Results**

On regression analysis with dependent variable as the pelvic node was analysed with age, depth of invasion and size of lesion and parametrium, none of factors were significantly influencing the nodal status.

Similarly, the parametrium positivity taken as the dependent variable was analysed with age, size of lesion, depth of invasion. None of the factors could predict the parametrial involvement. Overall 5-year survival probability for the patients is 0.770 i.e 55 months with 95% CI (0.570, 1.000). Here, the 5-year survival probability for the patients with parametrium positive status is 0.917 i.e 48 months 95% CI (0.773, 1.000). The log rank test for change in survival between two parametrium groups i.e., negative and positive patients gives chi-square value 3.59 (d.f.=1, p-value = 0.06), which indicates two groups do not differ in their survival.

Disease free survival of the parametrium –ve/ parametrium+ve(60/24 mths). The log rank test for change in survival between two parametrium groups i.e., negative and positive patients gives chi-square value 2.8 (d.f.=1, p-value = 0.1), which indicates two groups do not differ in their disease free survival.

**Conclusion**

The parametrium and nodal positivity of non-squamous cancers are not dependent on each other. Thus, we conclude from
Thus, we can subject the patients to either of a single modality of treatment i.e either a radical hysterectomy or ctrt.

References

1. Ali, F., Kuelker, R., & Wassie, B. (2012). Understanding cervical cancer in the context of developing countries. Annals of Tropical Medicine & Public Health, 5(1).
2. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., ... & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer, 136(5), E359-E386.
3. Bruni, J. E., Del Bigio, M. R., Cardoso, E. R., & Persaud, T. V. N. (1988). Neuropathology of congenital hydrocephalus in the SUMS/NP mouse. Acta neurochirurgica, 92(1), 118-122.
4. Sreedevi, A., Javed, R., & Dinesh, A. (2015). Epidemiology of cervical cancer with special focus on India. International journal of women's health, 7, 405.
5. Bernabeu Verdú, J., Grau Rubio, C., Founier del Castillo, C., Cañete Nieto, A., Menor Serrano, F., Suárez Rodríguez, J. M., & Castel Sánchez, V. (2006). Neuropsychological Rehabilitation in Pediatric Oncology: comparison of neuropsychological profiles after intervention.
6. Eifel, P. J., Morris, M., Oswald, M. J., Taylor Wharton, J., & Delclos, L. (1990). Adenocarcinoma of the uterine cervix prognosis and patterns of failure in 367 cases. Cancer, 65(11), 2507-2514.
7. Moon, C. H., Lee, S., Kim, I. K., Kim, H. I., Lee, Y. D., & Jeun, K. H. (1990). Introduction of Hospital Service Training Program (HSTP) to the Medical Education in Korea. Korean Journal of Medical Education, 2(2), 57-66.
8. Nagano, J., Kono, S., Preston, D. L., & Mabuchi, K. (2001). A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer causes & control, 12(6), 501-508.
9. Salvo, G., Frumovitz, M., Ramalingam, P., & Bhosale, P. (2021). Early-Stage High-Grade Neuroendocrine Cervical Carcinoma. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 31(8), 1179.